The drug is the only one the US Drug Enforcement Administration (FDA) believes works against the disease itself, and not against symptoms such as anxiety and sleep problems.
The medicine, developed by American Biogen and Japanese Eisai co., Is under discussion. One study showed that the medicine only slowed the mental decline, did not stop it.
The stock was paused before the news came on Monday afternoon.
Because of this, experts in the field fear that an approval will set a new precedent, which could open the doors for approval of treatments with questionable effects.
The FDA has asked companies to conduct a new study to confirm that the drug helps patients. If the study does not confirm that the medicine is effective, the FDA may withdraw the medicine from the market, although this is something they rarely do.
(©NTB)
– .
